Treatment of H. pylori infection: a review.

Marcello Candelli; Enrico Celestino Nista; Emilia Carloni; Giulia Pignataro; Maria Assunta Zocco; Immacolata Alessia Cazzato; Cristiana Di Campli; Lucia Fini; Giovanni Battista Gasbarrini; Antonio Gasbarrini

Treatment of H. pylori infection: a review.

Marcello Candelli
, Enrico Celestino Nista
, Emilia Carloni
, Giulia Pignataro
, Maria Assunta Zocco
, Immacolata Alessia Cazzato
, Cristiana Di Campli
, Lucia Fini
, Giovanni Battista Gasbarrini
, Antonio Gasbarrini

Research output: Contribution to journal › Article

Abstract

Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics. PMID: 15720247 [PubMed - indexed for MEDLINE]

Original language	English
Pages (from-to)	375-384
Number of pages	10
Journal	Current Medicinal Chemistry
Publication status	Published - 2005

Keywords

helicobacter pylori

Cite this

@article{c2b5dd4760364688a38b900e8fee9b0c,

title = "Treatment of H. pylori infection: a review.",

abstract = "Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics. PMID: 15720247 [PubMed - indexed for MEDLINE]",

keywords = "helicobacter pylori, helicobacter pylori",

author = "Marcello Candelli and Nista, \{Enrico Celestino\} and Emilia Carloni and Giulia Pignataro and Zocco, \{Maria Assunta\} and Cazzato, \{Immacolata Alessia\} and \{Di Campli\}, Cristiana and Lucia Fini and Gasbarrini, \{Giovanni Battista\} and Antonio Gasbarrini",

year = "2005",

language = "English",

pages = "375--384",

journal = "Current Medicinal Chemistry",

issn = "0929-8673",

publisher = "Bentham Science Publishers",

}

TY - JOUR

T1 - Treatment of H. pylori infection: a review.

AU - Candelli, Marcello

AU - Nista, Enrico Celestino

AU - Carloni, Emilia

AU - Pignataro, Giulia

AU - Zocco, Maria Assunta

AU - Cazzato, Immacolata Alessia

AU - Di Campli, Cristiana

AU - Fini, Lucia

AU - Gasbarrini, Giovanni Battista

AU - Gasbarrini, Antonio

PY - 2005

Y1 - 2005

N2 - Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics. PMID: 15720247 [PubMed - indexed for MEDLINE]

AB - Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics. PMID: 15720247 [PubMed - indexed for MEDLINE]

KW - helicobacter pylori

UR - http://hdl.handle.net/10807/21013

M3 - Article

SN - 0929-8673

SP - 375

EP - 384

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

ER -

Treatment of H. pylori infection: a review.

Abstract

Keywords

Other files and links

Fingerprint

Cite this